Lilly, which has its headquarters in Indianapolis, first announced that it would be seeking approval from Limerick City and ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster ...

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to ...

In anticipation of continued high demand, Eli Lilly has announced plans for a $4.5 billion investment in a new manufacturing site, the Lilly Medicine Foundry. This facility is expected to enhance ...

Eli Lilly has followed Novo Nordisk in announcing ... of a $6 billion investment in manufacturing capacity centred on a site in Denmark. Trulicity sales were $5.46 billion in the first nine ...

Merck is going all-in on domestic drug manufacturing with a $1 billion Delaware facility aimed at dodging Trump-era tariff ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...